Blue Jet Healthcare Limited has announced its unaudited standalone financial results for the quarter and half-year ended September 30, 2026. The company reported a profit of ₹1,025.17 million for the quarter and ₹1,807.81 million for the six-month period. Revenue from operations for the quarter stood at ₹3,757.44 million, with total comprehensive income also at ₹1,025.17 million.
Blue Jet Healthcare Announces Q2 FY27 Financial Results
Blue Jet Healthcare Limited has officially released its unaudited standalone financial results for the quarter and half-year that concluded on September 30, 2026. The Board of Directors approved these results during their meeting held on November 5, 2026.
Financial Performance Highlights
For the second quarter ended September 30, 2026, the company reported a profit after tax of ₹1,025.17 million. This compares to a profit of ₹782.64 million in the corresponding quarter of the previous year. Revenue from operations for the current quarter reached ₹3,757.44 million.
Looking at the six months ended September 30, 2026, the profit after tax was ₹1,807.81 million. The revenue from operations for this half-year period stood at ₹6,688.57 million. The total comprehensive income for the six-month period was also ₹1,807.81 million.
Key Financial Figures (in million)
Three Months Ended September 30, 2026 (Unaudited)
- Revenue from Operations: ₹3,757.44
- Other Income: ₹262.08
- Total Income: ₹4,019.52
- Total Expenses: ₹2,645.58
- Profit Before Tax: ₹1,373.94
- Tax Expense: ₹348.77
- Profit for the period: ₹1,025.17
- Total Comprehensive Income: ₹1,025.17
- Earnings Per Share (Basic): ₹5.46
Six Months Ended September 30, 2026 (Unaudited)
- Revenue from Operations: ₹6,688.57
- Other Income: ₹414.44
- Total Income: ₹7,103.01
- Total Expenses: ₹4,669.61
- Profit Before Tax: ₹2,433.40
- Tax Expense: ₹625.59
- Profit for the period: ₹1,807.81
- Total Comprehensive Income: ₹1,807.81
- Earnings Per Share (Basic): ₹10.00
The company’s balance sheet as of September 30, 2026, shows total assets of ₹25,838.78 million and total equity and liabilities of the same amount. Equity share capital stood at ₹378.55 million.
The financial results have been reviewed by the Audit Committee and approved by the Board of Directors, and also reviewed by the Statutory Auditor. The company is engaged in the manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, and APIs, constituting a single reportable business segment.
Source: BSE
